Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.